19 episodes

Dr. Bernard Monteleone, former Head of Cardiology at St. Francis Hospital in New York, gives an informed analysis of highly-anticipated trials and whether or not their findings could impact clinical practice guidelines and reduce the risk of cardiovascular disease.

Practice Impact Extra AccessCardiology

    • Science

Dr. Bernard Monteleone, former Head of Cardiology at St. Francis Hospital in New York, gives an informed analysis of highly-anticipated trials and whether or not their findings could impact clinical practice guidelines and reduce the risk of cardiovascular disease.

    19 COVID and Anticoagulants

    19 COVID and Anticoagulants

    COVID 19 has been associated with a number of life-threatening conditions beyond respiratory complications including blood clotting leading to potentially deadly thromboembolic events. In order to improve outcomes, should all hospital admitted COVID 19 patients receive anticoagulants?

    • 3 min
    18 REDUCE IT EPA: A New Era of CV Therapies

    18 REDUCE IT EPA: A New Era of CV Therapies

    The REDUCE-IT EPA trial assessed the association of EPA blood levels with outcomes from the REDUCE-IT Trial first published in 2019. Researchers found on treatment the higher the EPA blood level, the lower the rates of different cardiovascular events, deaths, and total mortality. Could this introduce a new era of CV therapies?

    • 3 min
    17 Heart Injury Caused by COVID-19

    17 Heart Injury Caused by COVID-19

    Two studies from academic hospitals in Wuhan, China, and a third from NYU find that COVID-19 can cause heart injury even in people without underlying heart issues. High mortality rates in patients with elevated TNT levels as well as elevated C-reactive and BMP levels were evident across the three studies. With so much more to learn from the virus, the long term cardiac effects for recovered patients is still a great unknown.

    • 5 min
    16 Abandoning Angina Gender Preconceptions

    16 Abandoning Angina Gender Preconceptions

    Backed by machine learning and statistical models that analyzed how patients described their heart attack symptoms based on patient gender and obstructive disease, the Hermes trial found these symptoms reported by 90% of men and women consistently similar.

    • 3 min
    15 Victoria Trial Favorable to Patients

    15 Victoria Trial Favorable to Patients

    The Victoria trial assessed the drug Vericiguat in patients with heart failure and reduced ejection fraction. Although the absolute reductions were small, decreases in hospitalization and CV deaths in patients 75 could see Vericiguat added as a treatment for very ill CHF patients.

    Research continues to find newer pharmacologic treatments to improve outcomes.

    • 3 min
    CIAO-Ischemia Study: Outcomes at One Year

    CIAO-Ischemia Study: Outcomes at One Year

    One year after the 2019 Ischemia trial assessed interventional treatment to drug therapy with established angina, ischemia, and stable obstructive coronary artery disease, Dr. Bernie breaks down outcomes related to symptoms and degree of ischemia.

    • 3 min

Top Podcasts In Science